OCREVUS is dosed twice yearly, with no mandatory ongoing laboratory monitoring

Doses of OCREVUS (ocrelizumab) must be separated by at least 20 weeks.

Pretreatment evaluation

  • Hepatitis B virus screening should be performed in all patients before initiation of treatment with OCREVUS
  • Administer all immunizations according to immunization guidelines at least 4 weeks prior to initiation of OCREVUS for live or live-attenuated vaccines and, whenever possible, at least 2 weeks prior to initiation of OCREVUS for non-live vaccines

Preparation before every infusion

Infection assessment
  • Determine whether there is an active infection. In case of active infection, delay infusion of OCREVUS until infection resolves
Recommended premedication
  • Premedicate with 100 mg IV methylprednisolone (or equivalent) approximately 30 minutes before each infusion
  • Premedicate with an antihistamine (eg, diphenhydramine) approximately 30 to 60 minutes prior to each OCREVUS infusion
  • The addition of an antipyretic (eg, acetaminophen) may also be considered

Delayed or missed doses

  • If a planned infusion of OCREVUS is missed, administer OCREVUS as soon as possible; do not wait until the next scheduled dose
  • Reset the dose schedule to administer the sequential dose 6 months (24 weeks) after the missed dose is administered

Recommended dose, infusion rate, and infusion duration for RMS and PPMS

*Infusion may take longer if the infusion is interrupted or slowed.
Administer the first subsequent dose 6 months after infusion 1 of the initial dose.
The Infusion Center Locator is non-medication and non-disease specific, so it contains sites that may not infuse OCREVUS or that may not be covered by a particular patient's insurance provider.

Solutions of OCREVUS for intravenous infusion are prepared by dilution of the drug product into an infusion bag containing 0.9% sodium chloride injection, to a final drug concentration of approximately 1.2 mg/mL.

View the full Prescribing Information for complete Dosage and Administration.


PPMS=primary progressive multiple sclerosis; RMS=relapsing multiple sclerosis.

Infusion Center Locator

The National Infusion Center Association (NICA) maintains an Infusion Center Locator, which helps connect patients with sites of infusion care in their communities.

Site of care and home infusions

Quality care can be achieved at different sites of infusion, including home infusion, under supervision of a healthcare professional. Find out more about Genentech’s philosophy on infusions.